Last reviewed · How we verify
Cystagon
At a glance
| Generic name | Cystagon |
|---|---|
| Also known as | cysteamine bitartrate |
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Cystinosis
Common side effects
- Vomiting
- Anorexia
- Fever
- Diarrhea
- Lethargy
- Rash
- Nausea
- Bad breath
- Abdominal pain
- Dyspepsia
- Constipation
- Gastroenteritis
Serious adverse events
- Renal failure
- Interstitial nephritis
- Seizures
- Encephalopathy
- Benign intracranial hypertension
- Gastrointestinal ulceration and bleeding
- Leukopenia
- Sudden deaths
- Ataxia
- Hallucinations
Key clinical trials
- Effectiveness of a Bilayering Serum and Cream Containing GABA, DMAE, Cysteamine, and Bakuchiol for Skin Whitening and Anti-Aging (PHASE2)
- Use of Cysteamine in the Treatment of Cystinosis
- Cystinosis and Mitochondrial Metabolism (NA)
- A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications (NA)
- PK and PD Study of NPI-001 and Cysteamine Bitartrate (PHASE1, PHASE2)
- DFT383 in Pediatric Participants With Nephropathic Cystinosis (PHASE1, PHASE2)
- A Study to Assess TTI-0102 vs Placebo in MELAS Patients (PHASE2)
- A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: